FinnCap restated their corporate rating on shares of Avacta Group Plc (LON:AVCT) in a report issued on Tuesday. FinnCap currently has a GBX 200 ($2.63) price target on the biotechnology company’s stock.

Avacta Group Plc (LON AVCT) opened at GBX 66.40 ($0.87) on Tuesday. Avacta Group Plc has a 12 month low of GBX 60 ($0.79) and a 12 month high of GBX 98 ($1.29).

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at

About Avacta Group Plc

Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.

Receive News & Ratings for Avacta Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.